<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997486</url>
  </required_header>
  <id_info>
    <org_study_id>1757716</org_study_id>
    <nct_id>NCT04997486</nct_id>
  </id_info>
  <brief_title>The Effect of Time-restricted Eating on Liver Metabolism</brief_title>
  <acronym>TREL</acronym>
  <official_title>The Effect of Time-restricted Eating on Liver Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous studies have established the role of nutrition on obesity and its related metabolic&#xD;
      diseases, which together affect a billion individuals worldwide. Evidence indicate that meal&#xD;
      timing regulates numerous metabolic processes suggesting that meal time manipulation may be a&#xD;
      simple intervention against obesity and its metabolic diseases. Time-restricted eating (TRE)&#xD;
      is a dietary manipulation that involves restricting food intake to 6-10 h/day with no energy&#xD;
      intake the rest of the day. In rodents, TRE significantly decreases hepatic steatosis and&#xD;
      dyslipidemia, while it supports a healthier hepatic cellular content even without caloric&#xD;
      restriction, potentially by alternating activation of nutrient sensing mechanisms and effects&#xD;
      on circadian oscillations. However, an understanding of the effect of TRE on liver health in&#xD;
      people is not clear. Accordingly, we will conduct a randomized controlled trial in people&#xD;
      with overweight/obesity and hepatic steatosis to determine the effect of 9 h TRE for 12&#xD;
      weeks, on key metabolic outcomes in liver health: 1) intrahepatic triglyceride content using&#xD;
      magnetic resonance imaging; 2) de novo lipogenesis during fasting and postprandial conditions&#xD;
      using administration of deuterated water in conjunction with mathematical modeling. The&#xD;
      proposed study will enable us to determine the effect of meal timing on metabolic function in&#xD;
      people with NAFLD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intrahepatic triglyceride (IHTG) content</measure>
    <time_frame>About 12 weeks</time_frame>
    <description>IHTG will be assessed by using MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in de novo lipogenesis (DNL)</measure>
    <time_frame>About 12 weeks</time_frame>
    <description>DNL will be assessed by using administration of deuterated water and measurement of deuterium enrichment in plasma lipids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose, free fatty acid and triglyceride levels in response to a meal</measure>
    <time_frame>Before and after 12 weeks</time_frame>
    <description>Postprandial metabolic homeostasis will be assessed by using a mixed meal tolerance test.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>NAFLD</condition>
  <condition>Obesity</condition>
  <condition>Nutritional and Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will consume all meals/snacks during a ~15-h daily eating period (~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRE isocaloric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRE ad libitum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting) without any other dietary advice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time restricted eating</intervention_name>
    <description>Participants will be asked consume all meals/snacks during a ~9-h daily eating period (~15-h fasting).</description>
    <arm_group_label>TRE ad libitum</arm_group_label>
    <arm_group_label>TRE isocaloric</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 25-75 years&#xD;
&#xD;
          -  men and women&#xD;
&#xD;
          -  body mass index 25-45 kg/m2&#xD;
&#xD;
          -  clinical diagnosis of NAFLD&#xD;
&#xD;
          -  self-reported habitual eating period more than or equal to 14 h per day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  shift worker, recent or expected travel crossing time zones&#xD;
&#xD;
          -  fasting &gt;12-h/day more than once a week&#xD;
&#xD;
             *&gt; once a week no food intake after 18:00&#xD;
&#xD;
          -  habitually waking up before 04:00 and sleeping before 22:30&#xD;
&#xD;
          -  unstable weight (&gt;5% change in the last 2 months)&#xD;
&#xD;
          -  diabetes mellitus or alcoholic liver disease&#xD;
&#xD;
          -  sleep disorder&#xD;
&#xD;
          -  history of or current eating disorder&#xD;
&#xD;
          -  cancer in last 5 years&#xD;
&#xD;
          -  conditions that render subject unable to complete all testing procedures&#xD;
&#xD;
          -  use of medications that affect the study outcome measures or increase the risk of&#xD;
             study procedures and that cannot be temporarily discontinued&#xD;
&#xD;
          -  smoking or illegal drug use&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  having metals in the body&#xD;
&#xD;
          -  cognitive impairment&#xD;
&#xD;
          -  gastrointestinal or bariatric surgery that affects nutrient digestion and absorption&#xD;
             unable to grant voluntary informed consent or comply with the study instructions&#xD;
             individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  individuals that are unable to lie motionless on the MRI scanner for an hour or *have&#xD;
             tattoos or tattooed eyeliner&#xD;
&#xD;
          -  alcohol abuse&#xD;
&#xD;
          -  prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Chondronikola, PhD, RDN</last_name>
    <phone>5307541977</phone>
    <email>mchondr@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616-5398</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Chondronikola, PhD, RDN</last_name>
      <phone>530-754-1977</phone>
      <email>mchondr@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Chondronikola, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

